In the open-label, monocentric phase II trial (NCT00988169), the efficacy of the combination with erlotinib and AT-101 was investigated in patients with advanced non-small cell lung cancer who were treatment-naive, and had epidermal growth factor receptor activating mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.